Key Drivers
- Liquidity strength
- Margin pressure
- Cash burn
AIAI Summary
SIBN has shifted from a “survival” story to a credible commercial execution story with strong revenue growth, record physician engagement, improving EBITDA, and a solid balance sheet, but the key investment question is whether it can convert its ~80% gross margins into sustained operating cash flow before valuation and reimbursement risk catch up.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity strength
- •Margin pressure
- •Cash burn
SIBN has a very strong balance sheet and solid gross margins, but persistent operating losses and negative cash flow mean it remains financially safe yet fundamentally unprofitable at a not-cheap valuation.
Price Behavior
Key Price Behavior Insights:
- •Flat Trend
- •Support Rebound
- •Mid-14s Cap
Over the last month, SIBN has traded flat overall but showed a sharp rebound off $11.61 support, while repeated failure in the $14.32-$14.60 zone leaves the short-term move constructive but unconfirmed.
Sharp early-May drop to $11.61, then a quick rebound to $14.60
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Margin Expansion
- •Guidance Raise
SI-BONE delivered a strong Q1 beat with 11% revenue growth, sharply improved EBITDA, and a higher 2026 outlook, signaling improving adoption and investor momentum.
The earnings update is likely supportive for SI-BONE shares as it reinforces accelerating demand, better profitability, and a more constructive full-year growth trajectory
Similar Companies in Healthcare
Other companies in the same sector with AI ratings